Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2020 / N 2

Использование комбинированных препаратов в лечении пациентов с сахарным диабетом 2-го типа
О.М. Котешкова, Н.А. Демидов, М.Б. Анциферов, О.В. Духарева

Список литературы

1. Анциферов М.Б., Демидов Н.А., Калашникова М.В., Духарева О.В., Викулова О.К., Шестакова М.В. Динамика основных эпидемиологических показателей у пациентов с сахарным диабетом, проживающих в Москве (2013-2018). Сахарный диабет 2020;23(2):113-24.
2. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., Колбин А.С., Рафальский В.В., Чеберда А.Е., Кантемирова М.А., Закиев В.Д., Фадеев В.В. Анализ стоимости болезни сахарного диабета 2 типа в Российской Федерации: результаты российского многоцентрового наблюдательного фармакоэпидемиологического исследования ФОРСАЙТ-СД2. Сахарный диабет 2017;20(6):403-19.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998 Sep;352(9131):837-53.
4. American Diabetes Association. Standards of medical care in diabetes – 2017: summary of revisions. Diabetes Care 2017 Jan;40(Suppl 1):S4-5.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. The Lancet 1998 Sep;352(9131):854-65.
6. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012 Apr;35(4):731-7.
7. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Annals of Internal Medicine 2012 Nov;157(9):601-10.
8. Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, Greevy RA Jr, Grijalva CG, Elasy TA, Griffin MR. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA 2019 Sep;322(12):1-11.
9. Flory JH, Hennessy S, Bailey CJ, Inzucchi SE. Reports of lactic acidosis attributed to metformin, 2015–2018. Diabetes Care 2020 Jan;43(1):244-6.
10. Lazarus B, Wu A, Shin JI, Sang Y, Alexander GC, Secora A, Incer LA, Coresh J, Chang AR, Grams ME. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. JAMA Internal Medicine 2018 Jul;178(7):903-10.
11. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999 Aug;42(8):903-19.
12. Kramer W, Müller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochimica et Biophysica Acta 1994 May;1191(2):278-90.
13. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Molecular Medicine 2000 Nov;6(11):907-33.
14. Müller G, Hartz D, Pünter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochimica et Biophysica Acta 1994 May;1191(2):267-77.
15. Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Annals of Pharmacotherapy 2004 Jan;38(1):30-5.
16. Matsuki M, Matsuda M, Kohara K, Shimoda M, Kanda Y, Tawaramoto K, Shigetoh M, Kawasaki F, Kotani K, Kaku K. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. Endocrine Journal 2007 Aug;54(4):571-6.
17. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996 Dec;39(12):1617-24.
18. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine 2008 Jun;358(24):2545-59.
19. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee G, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen EC, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travertet F; Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008 Jun;358(24):2560-72.
20. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine 2009 Jan;360(2):129-39.
21. Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes – more common than you think: a continuous glucose monitoring study. Journal of Diabetes Science and Technology 2015 Apr;9(5):999-1005.
22. Abdelmoneim AS, Eurich DT, Light PE, Senior PA, Seubert JM, Makowsky MJ, Simpson SH. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes, Obesity and Metabolism 2015 Jun;17(6):523-32.
23. Zareba W, Cygankiewicz I. The QT interval. In: Comprehensive electrocardiology. Macfarlane PW, van Oosterom A, Pahlm O, Kligfield P, Janse M, Camm J, editors. 2nd ed. London, UK: Springer; 2011: 834-62.
24. Middleton TL, Wong J, Molyneaux L, Brooks BA, Yue DK, Twigg SM, Wu T. Cardiac effects of sulfonylurea-related hypoglycemia. Diabetes Care 2017 May;40(5):663-70.
25. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Medicine 2001 Oct;18(10):828-34.
26. Pareek A, Chandurkar NB, Salkar HR, Borkar MS, Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. American Journal of Therapy 2013 Jan;20(1):41-7.
27. González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. Journal of Diabetes and its Complications 2009 Nov-Dec;23(6):376-9.
28. Мкртумян А.М. Результаты наблюдательного исследования ESCALATION: особенности применения глимепирида у пациентов с сахарным диабетом 2-го типа, не достигших целевых показателей углеводного обмена на фоне терапии ингибитором ДПП-4 в комбинации с метформином. Проблемы эндокринологии 2017;63(1):30-8.

References

1. Antsiferov MB, Demidov NA, Kalashnikova MV, Dukhareva OV, Vikulova OK, Shestakova MV. Dynamics of main epidemiological indicators in patients with diabetes mellitus living in Moscow (2013–2018). Diabetes Mellitus 2020;23(2):113-24 (In Russian).
2. Dedov II, Kalashnikova MF, Belousov DYu, Kolbin AS, Rafalskiy VV, Cheberda AE, Kantemirova MA, Zakiyev VD, Fadeyev VV. Cost analysis of type 2 diabetes in the Russian Federation: results of Russian multicenter observational pharmacoepidemiological study FORESIGHT-DM2. Diabetes Mellitus 2017;20(6):403-19 (In Russian).
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998 Sep;352(9131):837-53.
4. American Diabetes Association. Standards of medical care in diabetes – 2017: summary of revisions. Diabetes Care 2017 Jan;40(Suppl 1):S4-5.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. The Lancet 1998 Sep;352(9131):854-65.
6. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012 Apr;35(4):731-7.
7. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Annals of Internal Medicine 2012 Nov;157(9):601-10.
8. Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, Greevy RA Jr, Grijalva CG, Elasy TA, Griffin MR. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA 2019 Sep;322(12):1-11.
9. Flory JH, Hennessy S, Bailey CJ, Inzucchi SE. Reports of lactic acidosis attributed to metformin, 2015–2018. Diabetes Care 2020 Jan;43(1):244-6.
10. Lazarus B, Wu A, Shin JI, Sang Y, Alexander GC, Secora A, Incer LA, Coresh J, Chang AR, Grams ME. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. JAMA Internal Medicine 2018 Jul;178(7):903-10.
11. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999 Aug;42(8):903-19.
12. Kramer W, Müller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochimica et Biophysica Acta 1994 May;1191(2):278-90.
13. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Molecular Medicine 2000 Nov;6(11):907-33.
14. Müller G, Hartz D, Pünter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochimica et Biophysica Acta 1994 May;1191(2):267-77.
15. Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Annals of Pharmacotherapy 2004 Jan;38(1):30-5.
16. Matsuki M, Matsuda M, Kohara K, Shimoda M, Kanda Y, Tawaramoto K, Shigetoh M, Kawasaki F, Kotani K, Kaku K. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. Endocrine Journal 2007 Aug;54(4):571-6.
17. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996 Dec;39(12):1617-24.
18. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine 2008 Jun;358(24):2545-59.
19. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee G, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen EC, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travertet F; Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008 Jun;358(24):2560-72.
20. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine 2009 Jan;360(2):129-39.
21. Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes – more common than you think: a continuous glucose monitoring study. Journal of Diabetes Science and Technology 2015 Apr;9(5):999-1005.
22. Abdelmoneim AS, Eurich DT, Light PE, Senior PA, Seubert JM, Makowsky MJ, Simpson SH. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes, Obesity and Metabolism 2015 Jun;17(6):523-32.
23. Zareba W, Cygankiewicz I. The QT interval. In: Comprehensive electrocardiology. Macfarlane PW, van Oosterom A, Pahlm O, Kligfield P, Janse M, Camm J, editors. 2nd ed. London, UK: Springer; 2011: 834-62.
24. Middleton TL, Wong J, Molyneaux L, Brooks BA, Yue DK, Twigg SM, Wu T. Cardiac effects of sulfonylurea-related hypoglycemia. Diabetes Care 2017 May;40(5):663-70.
25. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Medicine 2001 Oct;18(10):828-34.
26. Pareek A, Chandurkar NB, Salkar HR, Borkar MS, Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. American Journal of Therapy 2013 Jan;20(1):41-7.
27. González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. Journal of Diabetes and its Complications 2009 Nov-Dec;23(6):376-9.
28. Mkrtumyan AM. Glimepiride in patients with type 2 diabetes mellitus unreached target indicators of carbohydrate metabolism during therapy with a DPP-4 inhibitor and metformin: results of observational study ESCALATION. Problems of Endocrinology 2017;63(1):30-8 (In Russian).
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]